Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours

International Journal of Cancer

Volumn 70, Issue 5, 1997, Pages 508-511

  Shih, Yang Chia ^a   Kerr, Judith ^a   Liu, Jim ^b   Hurst, Terry ^c   Khoo, Soo Keat ^c   Ward, Bruce ^c   Wainwright, Brandon ^c   Chenevix Trench, Georgia ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Myriad Genetic Laboratories   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2A; UNCLASSIFIED DRUG;

ARTICLE; DNA METHYLATION; FEMALE; GENE DELETION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BLOTTING, SOUTHERN; CARCINOMA; CARRIER PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030895616     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.0.CO;2-1     Document Type: Article

References (27)

1. CAMPBELL, I.G., BEYNON, G., DAVIS, M. and ENGLEEIELD, P., LOH and mutation analysis of CDKN2A in primary human ovarian cancers. Int. J. Cancer, 63, 222-225 (1995).
2. CHENEVIX-TRENCH, G., KERR, J., FRIEDLANDER, M., HURST, T., SANDERSON, B., COGLAN, M., WARD, B., LEARY, J. and KHOO, S.K., Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumours. Amer. J. hum. Genet., 55, 143-149 (1994).
3. CHENEVIX-TRENCH, G. and 19 OTHERS, Analysis of loss of heterozygosity and K-ras mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer (1997) (In press).
4. CHENEVIX-TRENCH, G., LEARY, J., KERR. J., MICHEL, J., KEFFORD, R., HURST, T., PARSONS, P.G., FRIEDLANDER, M. and KHOO, S.K., Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene, 7, 1059-1065 (1992).
5. CLIBY, W., RITLAND, S., HARTMANN, L., DOBSON, M., HALLING, K.C., KEENEY, G., PODRATZ, K.C. and JENKINS, R.B., Human epithelial ovarian cancer allelotype. Cancer Res., 53, 2393-2398 (1993).
6. DEVLIN, J., ELDER. P.A., GABRA, H., STEEL, C.M. and KNOWLES, M.A., High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Brit. J. Cancer, 73, 420-423 (1996).
7. DEVLIN, J., KEEN, A.J. and KNOWLES, M.A., Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene, 9, 2757-2760 (1994).
8. EIRIKSDOTTIR, G., SIGURDSSON, A., JONASSON, J.G., AGNARSSON, B.A., SIGURDSSON, H., GUDMMUNDSSON, J.T., BERGTHJORSSON, J.T., BARKARDOT-TIR, R.B., EGILSSON, V. and INGVARSSON, S., Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int. J. Cancer, 64, 378-382 (1995).
9. INK4A). Carcinogenesis (1996) (In press).
10. HATTA, Y., HIRAMA, T., TAKEUCHI, S., LEE, E., PHAM, E., MILLER, C.W., STROHMEYER, T., WILCZYNSKI, S.P., MELMED, S. and KOKFFLER, H.P.,Alterations of the p16 (MTS1) gene in testicular, ovarian and endometrial malignancies. J. Urology, 154, 1954-1957 (1995).
11. INK4B1. Cancer Res., 56, 722-727 (1996).
12. HERMAN, J.G., MERLO, A., MAO, L., LAPIDUS, R.G., OSSA, J.P.J., DAVIDSON, N.E., SIDRANSKY, D. and BAYLIN, S.B., Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-1530 (1995).
13. KAMB, A., CRUIS, N.A., WEAVRR-FELDHAUS. J., LUI, Q., HARSHMAN. K., TAVTIGIAN, S.V., STUCKERT, E., DAY III, R.S., JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in eenesis of many tumour types. Science. 264, 436-440 (1994).
14. KISHIMOTO, Y., SUGIO, K., HUNG, J.Y., VIRMANU A.K., MCLNTIRE, D.D., MINNA, J.D. and GAZDAR, A.F., Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lune cancers. J. nat. Cancer Inst., 87, 1224-1229 (1995).
15. LEGGETT, B.A., YOUNG, J.P., BUTTENSHAW, R., THOMAS, L.R., YOUNG, B., CHENEVIX-TRENCH, G., SEARLE, J. and WARD, M. Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. Brit. J. Cancer, 71, 1070-1073 (1995).
16. Liu, Q., NEUHAUSEN, S., MCCLURE, M., FRYE, C., WEAVER-FELDHAUS, J., GRUIS, N.A., EDDINGTON, K., ALLALUNIS, M.J., SKOLNICK, H.M., FUJIMURA, F.K. and KAMB, A., CDKN2A (MTSI) tumour suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067 (1995).
17. MERLO, A., HERMAN, J.G., MAO, L., LEE, D.J., GABRIELSON, E., BURGER, P.C., BAYLIN, S.B. and SIDRANSKY, D., 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nature (Med.), 1, 686-692 (1995).
18. NOBORI, T., MIURA, K., Wu, D.J., Lois, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
19. OKAJIMA, E., FUKUDA, T., OKITA, S., TSUTSUMI, M., HIRAO, Y., OKAJIMA, E. and KONISHI, Y., Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett., 203, 227-231 (1996).
20. OSBORNE, R.J. and LEECH, V., Polymerase chain reaction allelotyping of human ovarian cancer. Brit. J. Cancer, 69, 429-438 (1994a).
21. OSBORNE, R.J. and LEECH, V., Chromosome 9q deletion mapping in epithelial ovarian cancer. Proc. Amer. Assoc. Cancer Res., 35, 601 (1994b).
22. OTTERSON, G.A., KHLEIF, S.N., CHEN, W., COXON, A.B. and KAYE, F.J., CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene, 11, 1211-1216 (1995).
23. RODABAUGH, K.J., BIGGS, R.B., QURESHI, J.A., BARRETT, A.J., WILLIAM, R.W., BELL, D.A., BERKOWITZ, R.S. and MOK, S., Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumours. Oncogene, 11, 1249-1254 (1995).
24. SCHULTZ, D.C., VANDERVEER, L., BUETOW, K.H., BOENTE, M.P., OZOLS, R.F., HAMILTON, T.C. and GODWIN, A.K., Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res., 55, 2150-2157 (1995).
25. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
26. SHELLING, A.N., COOKE, I.E. and GANESAN, T.S., The genetic analysis of ovarian cancer. Brit. J. Cancer, 72, 521-527 (1995).
27. TENERIELLO, M.G., EBINA, M., LINNOILA, R.I., HENRY, M., NASH, J.D., PARK, R.C. and BIRRER, M.J., p53 and Ki-ras sene mutations in epithelial ovarian neoplasms. Cancer Res., 53, 3103-3108 (1993).